Trial Search Results
Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer
The investigators hope to learn whether perfusion CT is a useful way to assess primary cervical tumor microenvironment and whether there is a relationship between pretreatment perfusion CT measurements and primary cervical tumor size, lymph node involvement (as assessed by standard of care pretreatment fludeoxyglucose Positron emission tomography/CT (FDG-PET/CT)), and treatment response (as assessed by standard of care 3-month post-therapy FDG-PET/CT).
Stanford is currently accepting patients for this trial.
- >18 years old
- with biopsy-proven squamous, adenocarcinoma or adenosquamous cervical cancer
- no history of prior pelvic radiation and should be able to receive chemoradiation
- non-pregnant women who have not previously undergone a hysterectomy, as that would
have removed the cervix.
- able to give informed consent
- Subjects whose tumors are not FDG avid on the pre-therapy PET.
- Allergy or inability to receive iodinated CT contrast
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study